Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-B167 alone and with tislelizumab in advanced solid tumors
NCT05494762Phase 1Terminated
- Sponsor
- BeiGene
- Start
- Aug 2022
- Primary completion
- Feb 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of BGB-B167 in solid tumor (2 arms), sponsored by BeiGene. Primary endpoints: Number of Participants Experiencing Adverse Events at 3 years, Number of Participants Experiencing Serious Adverse Events at 3 years and 4 more. Started Aug 2022; status: terminated.
02
Drugs
BGB-B167
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05494762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494762.